Back to top

Image: Bigstock

BioTelemetry (BEAT) Stock Moves -0.56%: What You Should Know

Read MoreHide Full Article

BioTelemetry (BEAT - Free Report) closed the most recent trading day at $59.05, moving -0.56% from the previous trading session. This change was narrower than the S&P 500's 1.54% loss on the day. Meanwhile, the Dow lost 1.49%, and the Nasdaq, a tech-heavy index, lost 2.17%.

Prior to today's trading, shares of the heart monitoring device maker had lost 0.9% over the past month. This has was narrower than the Medical sector's loss of 6.36% and the S&P 500's loss of 6.77% in that time.

Investors will be hoping for strength from BEAT as it approaches its next earnings release, which is expected to be February 28, 2019. In that report, analysts expect BEAT to post earnings of $0.42 per share. This would mark year-over-year growth of 31.25%. Our most recent consensus estimate is calling for quarterly revenue of $103.02 million, up 12.29% from the year-ago period.

BEAT's full-year Zacks Consensus Estimates are calling for earnings of $1.81 per share and revenue of $398.90 million. These results would represent year-over-year changes of +86.6% and +39.1%, respectively.

Any recent changes to analyst estimates for BEAT should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.

Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.

Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection has moved 0.46% higher. BEAT is holding a Zacks Rank of #1 (Strong Buy) right now.

Looking at its valuation, BEAT is holding a Forward P/E ratio of 32.9. This valuation marks a premium compared to its industry's average Forward P/E of 20.05.

It is also worth noting that BEAT currently has a PEG ratio of 3.29. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. Medical Services stocks are, on average, holding a PEG ratio of 1.28 based on yesterday's closing prices.

The Medical Services industry is part of the Medical sector. This group has a Zacks Industry Rank of 83, putting it in the top 32% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.


See More Zacks Research for These Tickers


Normally $25 each - click below to receive one report FREE:


HeartBeam, Inc. (BEAT) - free report >>

Published in